2-Methylimidazo[1,2-a]pyridin-8-ol

Catalog No. :
ACVOXS632
CAS No. :
79707-11-2
Molecular Formula :
C8H8N2O
Molecular Weight :
148.16

IUPAC Name:2-methylimidazo[1,2-a]pyridin-8-ol

2-Methylimidazo[1,2-a]pyridin-8-ol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$58.00Login to see priceIn stockInquiry
1g95%$157.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Methylimidazo[1,2-a]pyridin-8-ol
IUPAC Name2-methylimidazo[1,2-a]pyridin-8-ol
MDL No.MFCD05863338
Molecular FormulaC8H8N2O
Molecular Weight148.16
SMILESOC1=CC=CN2C1=NC(C)=C2
InChI KeyQWKYLVGNKWERLC-UHFFFAOYSA-N
Synonym2-methylimidazo[1,2-a]pyridin-8-ol | 79707-11-2 | 2-Methyl-imidazo[1,2-a]pyridin-8-ol | MFCD05863338 | 8-Hydroxy-2-methylimidazo[1,2-a]pyridine | Imidazo[1,2-a]pyridin-8-ol, 2-methyl- | SCHEMBL4003688 | DTXSID80356259 | QWKYLVGNKWERLC-UHFFFAOYSA-N | AKOS006241779 | AM807104 |
CAS No.79707-11-2
PubChem CID820953

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACVOXS632 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACVNMY715 route compound structure diagram
    ACVNMY71516867-03-1 In Stock
  4. Then
  5. ACVOXS632 route product structure diagram
    ACVOXS63279707-11-2 In Stock
Inquiry

2. ACVOXS632 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACQVKH312 route compound structure diagram
    ACQVKH3121184-54-9 In Stock
  4. Plus
  5. ACVNMY715 route compound structure diagram
    ACVNMY71516867-03-1 In Stock
  6. Then
  7. ACVOXS632 route product structure diagram
    ACVOXS63279707-11-2 In Stock
Inquiry

Comments (0)